Lung
Breast
Gastric
Nasopharyngeal.jpg)
.png)
| Target |
Microtubule Stabilizer |
| Indication |
Gastric Cancer
Breast Cancer
Solid Tumors（Combination Therapy）
|
Commercial RightGreater China |
|
| Profile |
TCMReduce wound inflammation Increase epithelialization of epidermal tissues Promote collagen production Reduce formation of wound granulation tissues |
| Target |
N/A |
|
Indication/ |
Diabetic Foot Ulcer
|
| Profile |
Oral small molecule TKI targeting FGFR1-3, VEGFR1-3, PDGFR α/β, with significant efficacy and high safety Rapid oral absorption, with little food effects on PK Pivotal Phase II study ongoing in multiple sites nationwide for the treatment of various types of tumors Explore combinations with PD-1/PD-L1 antibody |
| Target |
FGFR1-3 |
|
Indication/ |
Thymic Cancer
|
| Target |
VEGFR1-3 |
|
Indication/ Potential indication |
Nasopharyngeal Carcinoma
|
| Target |
PDGFR α/β |
|
Indication/ Potential indication |
Small Cell Lung Cancer
|
| Profile |
Clinical development strategy guided by unique biomarkers High selectivity to c-Met and long half-life Multiple studies ongoing in China/Japan/US; preliminary clinical efficacy hasbeen observed, with good safety |
| Target |
c-Met |
|
Indication/ Potential indication |
Exon-14 Skipping in Non-small Cell Lung Cancer
c-Met Mutation in Non-small Cell Lung Cancer
c-Met Mutation in Non-small Cell Lung Cancer
|
| Profile |
Highly active PI3Kα inhibitor Clinical development strategy guided by unique biomarkers Significant in vivo/vitro anti-tumor effects Preferable safety profile with little and reversible glycemia effects |
| Target |
c-Met |
|
Indication/ |
Solid tumor
Solid tumor
Breast Cancer
|